Impact of Fecal Microbiota Transplantation on Obesity and Metabolic Syndrome-A Systematic Review

Zhengxiao Zhang, Valentin Mocanu, Chenxi Cai, Jerry Dang, Linda Slater, Edward C Deehan, Jens Walter, Karen L Madsen, Zhengxiao Zhang, Valentin Mocanu, Chenxi Cai, Jerry Dang, Linda Slater, Edward C Deehan, Jens Walter, Karen L Madsen

Abstract

Fecal microbiota transplantation (FMT) is a gut microbial-modulation strategy that has been investigated for the treatment of a variety of human diseases, including obesity-associated metabolic disorders. This study appraises current literature and provides an overview of the effectiveness and limitations of FMT as a potential therapeutic strategy for obesity and metabolic syndrome (MS). Five electronic databases and two gray literature sources were searched up to 10 December 2018. All interventional and observational studies that contained information on the relevant population (adult patients with obesity and MS), intervention (receiving allogeneic FMT) and outcomes (metabolic parameters) were eligible. From 1096 unique citations, three randomized placebo-controlled studies (76 patients with obesity and MS, body mass index = 34.8 ± 4.1 kg/m2, fasting plasma glucose = 5.8 ± 0.7 mmol/L) were included for review. Studies reported mixed results with regards to improvement in metabolic parameters. Two studies reported improved peripheral insulin sensitivity (rate of glucose disappearance, RD) at 6 weeks in patients receiving donor FMT versus patients receiving the placebo control. In addition, one study observed lower HbA1c levels in FMT patients at 6 weeks. No differences in fasting plasma glucose, hepatic insulin sensitivity, body mass index (BMI), or cholesterol markers were observed between two groups across all included studies. While promising, the influence of FMT on long-term clinical endpoints needs to be further explored. Future studies are also required to better understand the mechanisms through which changes in gut microbial ecology and engraftment of microbiota affect metabolic outcomes for patients with obesity and MS. In addition, further research is needed to better define the optimal fecal microbial preparation, dosing, and method of delivery.

Keywords: fecal microbiota transplantation; gut microbiome; insulin sensitivity; metabolic syndrome; microbial ecology; obesity.

Conflict of interest statement

All other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
Figure 2
Figure 2
Mechanistic aspects of fecal microbiota transplantation (FMT) in obesity and metabolic syndrome (MS) requiring targeted research.

References

    1. WHO Obesity and Overweight. [(accessed on 16 February 2018)]; Available online:
    1. O’Neill S., O’Driscoll L. Metabolic syndrome: A closer look at the growing epidemic and its associated pathologies. Obes. Rev. 2015;16:1–12. doi: 10.1111/obr.12229.
    1. Saklayen M.G. The Global Epidemic of the Metabolic Syndrome. Curr. Hypertens. Rep. 2018;20:12. doi: 10.1007/s11906-018-0812-z.
    1. Bomberg E., Birch L., Endenburg N., German A.J., Neilson J., Seligman H., Takashima G., Day M.J. The Financial Costs, Behaviour and Psychology of Obesity: A One Health Analysis. J. Comp. Pathol. 2017;156:310–325. doi: 10.1016/j.jcpa.2017.03.007.
    1. Sullivan A.N., Lachman M.E. Behavior Change with Fitness Technology in Sedentary Adults: A Review of the Evidence for Increasing Physical Activity. Front Public Health. 2016;4:289. doi: 10.3389/fpubh.2016.00289.
    1. Burgess E., Hassmen P., Pumpa K.L. Determinants of adherence to lifestyle intervention in adults with obesity: A systematic review. Clin. Obes. 2017;7:123–135. doi: 10.1111/cob.12183.
    1. Yancy W.S., Jr., Olsen M.K., Guyton J.R., Bakst R.P., Westman E.C. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: A randomized, controlled trial. Ann. Int. Med. 2004;140:769–777. doi: 10.7326/0003-4819-140-10-200405180-00006.
    1. Mehta A., Marso S.P., Neeland I.J. Liraglutide for weight management: A critical review of the evidence. Obes. Sci. Pract. 2017;3:3–14. doi: 10.1002/osp4.84.
    1. le Roux C.W., Astrup A., Fujioka K., Greenway F., Lau D.C.W., Van Gaal L., Ortiz R.V., Wilding J.P.H., Skjoth T.V., Manning L.S., et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: A randomised, double-blind trial. Lancet. 2017;389:1399–1409. doi: 10.1016/S0140-6736(17)30069-7.
    1. Tek C. Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: Patient selection and perspectives. Patient Prefer Adherence. 2016;10:751–759. doi: 10.2147/PPA.S84778.
    1. Pinkney J., Kerrigan D. Current status of bariatric surgery in the treatment of type 2 diabetes. Obes. Rev. 2004;5:69–78. doi: 10.1111/j.1467-789X.2004.00119.x.
    1. Peterli R., Wolnerhanssen B.K., Peters T., Vetter D., Kroll D., Borbely Y., Schultes B., Beglinger C., Drewe J., Schiesser M., et al. Effect of Laparoscopic Sleeve Gastrectomy vs. Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. JAMA. 2018;319:255–265. doi: 10.1001/jama.2017.20897.
    1. Schauer P.R., Bhatt D.L., Kirwan J.P., Wolski K., Aminian A., Brethauer S.A., Navaneethan S.D., Singh R.P., Pothier C.E., Nissen S.E., et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes—5-Year Outcomes. N. Engl. J. Med. 2017;376:641–651. doi: 10.1056/NEJMoa1600869.
    1. Sender R., Fuchs S., Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016;14:e1002533. doi: 10.1371/journal.pbio.1002533.
    1. Turnbaugh P.J., Ley R.E., Hamady M., Fraser-Liggett C.M., Knight R., Gordon J.I. The human microbiome project. Nature. 2007;449:804–810. doi: 10.1038/nature06244.
    1. Baktash A., Terveer E.M., Zwittink R.D., Hornung B.V.H., Corver J., Kuijper E.J., Smits W.K. Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of Clostridium difficile Infections. Front. Microbiol. 2018;9:1242. doi: 10.3389/fmicb.2018.01242.
    1. Brahe L.K., Astrup A., Larsen L.H. Can We Prevent Obesity-Related Metabolic Diseases by Dietary Modulation of the Gut Microbiota? Adv. Nutr. 2016;7:90–101. doi: 10.3945/an.115.010587.
    1. He M., Shi B. Gut microbiota as a potential target of metabolic syndrome: The role of probiotics and prebiotics. Cell Biosci. 2017;7:54. doi: 10.1186/s13578-017-0183-1.
    1. Wortelboer K., Nieuwdorp M., Herrema H. Fecal microbiota transplantation beyond Clostridioides difficile infections. EBioMedicine. 2019 doi: 10.1016/j.ebiom.2019.05.066.
    1. Tamboli C.P., Neut C., Desreumaux P., Colombel J.F. Dysbiosis in inflammatory bowel disease. Gut. 2004;53:1–4. doi: 10.1136/gut.53.1.1.
    1. Walker A.W., Lawley T.D. Therapeutic modulation of intestinal dysbiosis. Pharmacol. Res. 2013;69:75–86. doi: 10.1016/j.phrs.2012.09.008.
    1. Machiels K., Joossens M., Sabino J., De Preter V., Arijs I., Eeckhaut V., Ballet V., Claes K., Van Immerseel F., Verbeke K., et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–1283. doi: 10.1136/gutjnl-2013-304833.
    1. Scheithauer T.P., Dallinga-Thie G.M., de Vos W.M., Nieuwdorp M., van Raalte D.H. Causality of small and large intestinal microbiota in weight regulation and insulin resistance. Mol. Metab. 2016;5:759–770. doi: 10.1016/j.molmet.2016.06.002.
    1. Duranti S., Ferrario C., van Sinderen D., Ventura M., Turroni F. Obesity and microbiota: An example of an intricate relationship. Genes Nutr. 2017;12:18. doi: 10.1186/s12263-017-0566-2.
    1. Ley R.E., Backhed F., Turnbaugh P., Lozupone C.A., Knight R.D., Gordon J.I. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. USA. 2005;102:11070–11075. doi: 10.1073/pnas.0504978102.
    1. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–1031. doi: 10.1038/nature05414.
    1. Ridaura V.K., Faith J.J., Rey F.E., Cheng J., Duncan A.E., Kau A.L., Griffin N.W., Lombard V., Henrissat B., Bain J.R., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341:1241214. doi: 10.1126/science.1241214.
    1. Vindigni S.M., Surawicz C.M. Fecal Microbiota Transplantation. Gastroenterol. Clin. North Am. 2017;46:171–185. doi: 10.1016/j.gtc.2016.09.012.
    1. Wilson B.C., Vatanen T., Cutfield W.S., O’Sullivan J.M. The Super-Donor Phenomenon in Fecal Microbiota Transplantation. Front. Cell Infect. Microbiol. 2019;9:2. doi: 10.3389/fcimb.2019.00002.
    1. Kriss M., Hazleton K.Z., Nusbacher N.M., Martin C.G., Lozupone C.A. Low diversity gut microbiota dysbiosis: Drivers, functional implications and recovery. Curr. Opin. Microbiol. 2018;44:34–40. doi: 10.1016/j.mib.2018.07.003.
    1. Li Y.T., Cai H.F., Wang Z.H., Xu J., Fang J.Y. Systematic review with meta-analysis: Long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment. Pharmacol. Ther. 2016;43:445–457. doi: 10.1111/apt.13492.
    1. Quraishi M.N., Widlak M., Bhala N., Moore D., Price M., Sharma N., Iqbal T.H. Systematic review with meta-analysis: The efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment. Pharmacol. Ther. 2017;46:479–493. doi: 10.1111/apt.14201.
    1. Hui W., Li T., Liu W., Zhou C., Gao F. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis. PLoS ONE. 2019;14:e0210016. doi: 10.1371/journal.pone.0210016.
    1. Khanna S., Vazquez-Baeza Y., Gonzalez A., Weiss S., Schmidt B., Muniz-Pedrogo D.A., Rainey J.F., III, Kammer P., Nelson H., Sadowsky M., et al. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease. Microbiome. 2017;5:55. doi: 10.1186/s40168-017-0269-3.
    1. Theriot C.M., Young V.B. Interactions between the Gastrointestinal Microbiome and Clostridium difficile. Annu. Rev. Microbiol. 2015;69:445–461. doi: 10.1146/annurev-micro-091014-104115.
    1. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097.
    1. Borody T.J., Khoruts A. Fecal microbiota transplantation and emerging applications. Nat. Rev. Gastroenterol. Hepatol. 2011;9:88–96. doi: 10.1038/nrgastro.2011.244.
    1. Walter J., Maldonado-Gomez M.X., Martinez I. To engraft or not to engraft: An ecological framework for gut microbiome modulation with live microbes. Curr. Opin. Biotechnol. 2018;49:129–139. doi: 10.1016/j.copbio.2017.08.008.
    1. Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [(accessed on 26 June 2019)]; Updated March 2011. The Cochrane Collaboration. Available online: .
    1. Vrieze A., Van Nood E., Holleman F., Salojarvi J., Kootte R.S., Bartelsman J.F., Dallinga-Thie G.M., Ackermans M.T., Serlie M.J., Oozeer R., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913–916. doi: 10.1053/j.gastro.2012.06.031.
    1. Kootte R.S., Levin E., Salojarvi J., Smits L.P., Hartstra A.V., Udayappan S.D., Hermes G., Bouter K.E., Koopen A.M., Holst J.J., et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab. 2017;26:611–619. doi: 10.1016/j.cmet.2017.09.008.
    1. Smits L.P., Kootte R.S., Levin E., Prodan A., Fuentes S., Zoetendal E.G., Wang Z., Levison B.S., Cleophas M.C.P., Kemper E.M., et al. Effect of Vegan Fecal Microbiota Transplantation on Carnitine- and Choline-Derived Trimethylamine-N-Oxide Production and Vascular Inflammation in Patients with Metabolic Syndrome. J. Am. Heart Assoc. 2018;7 doi: 10.1161/JAHA.117.008342.
    1. Rowland I., Gibson G., Heinken A., Scott K., Swann J., Thiele I., Tuohy K. Gut microbiota functions: Metabolism of nutrients and other food components. Eur. J. Nutr. 2018;57:1–24. doi: 10.1007/s00394-017-1445-8.
    1. Baxter N.T., Schmidt A.W., Venkataraman A., Kim K.S., Waldron C., Schmidt T.M. Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers. MBio. 2019;10 doi: 10.1128/mBio.02566-18.
    1. Tolhurst G., Heffron H., Lam Y.S., Parker H.E., Habib A.M., Diakogiannaki E., Cameron J., Grosse J., Reimann F., Gribble F.M. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61:364–371. doi: 10.2337/db11-1019.
    1. McNabney S.M., Henagan T.M. Short Chain Fatty Acids in the Colon and Peripheral Tissues: A Focus on Butyrate, Colon Cancer, Obesity and Insulin Resistance. Nutrients. 2017;9 doi: 10.3390/nu9121348.
    1. Holst J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007;87:1409–1439. doi: 10.1152/physrev.00034.2006.
    1. De Vadder F., Kovatcheva-Datchary P., Goncalves D., Vinera J., Zitoun C., Duchampt A., Backhed F., Mithieux G. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014;156:84–96. doi: 10.1016/j.cell.2013.12.016.
    1. Petersen C., Bell R., Klag K.A., Lee S.-H., Soto R., Ghazaryan A., Buhrke K., Ekiz H.A., Ost K.S., Boudina S., et al. T cell–mediated regulation of the microbiota protects against obesity. Science. 2019;365:eaat9351. doi: 10.1126/science.aat9351.
    1. Everard A., Belzer C., Geurts L., Ouwerkerk J.P., Druart C., Bindels L.B., Guiot Y., Derrien M., Muccioli G.G., Delzenne N.M., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. USA. 2013;110:9066–9071. doi: 10.1073/pnas.1219451110.
    1. Shin N.R., Lee J.C., Lee H.Y., Kim M.S., Whon T.W., Lee M.S., Bae J.W. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014;63:727–735. doi: 10.1136/gutjnl-2012-303839.
    1. Anhe F.F., Roy D., Pilon G., Dudonne S., Matamoros S., Varin T.V., Garofalo C., Moine Q., Desjardins Y., Levy E., et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut. 2015;64:872–883. doi: 10.1136/gutjnl-2014-307142.
    1. Dao M.C., Everard A., Aron-Wisnewsky J., Sokolovska N., Prifti E., Verger E.O., Kayser B.D., Levenez F., Chilloux J., Hoyles L., et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: Relationship with gut microbiome richness and ecology. Gut. 2016;65:426–436. doi: 10.1136/gutjnl-2014-308778.
    1. Plovier H., Everard A., Druart C., Depommier C., Van Hul M., Geurts L., Chilloux J., Ottman N., Duparc T., Lichtenstein L., et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 2017;23:107–113. doi: 10.1038/nm.4236.
    1. Yamaguchi Y., Adachi K., Sugiyama T., Shimozato A., Ebi M., Ogasawara N., Funaki Y., Goto C., Sasaki M., Kasugai K. Association of Intestinal Microbiota with Metabolic Markers and Dietary Habits in Patients with Type 2 Diabetes. Digestion. 2016;94:66–72. doi: 10.1159/000447690.
    1. Gentile C.L., Weir T.L. The gut microbiota at the intersection of diet and human health. Science. 2018;362:776–780. doi: 10.1126/science.aau5812.
    1. Lynch K.E., Parke E.C., O’Malley M.A. How Causal are Microbiomes? A Comparison with the Helicobacter pylori Explanation of Ulcers. Biol. Philos. 2019;pitt philsci:15777.
    1. Armour C.R., Nayfach S., Pollard K.S., Sharpton T.J. A Metagenomic Meta-analysis Reveals Functional Signatures of Health and Disease in the Human Gut Microbiome. mSystems. 2019;4 doi: 10.1128/mSystems.00332-18.
    1. Tannock G.W. Understanding the Gut Microbiota. John Wiley & Sons; Hoboken, NJ, USA: 2017.
    1. Mallon C.A., Elsas J.D.V., Salles J.F. Microbial invasions: The process, patterns, and mechanisms. Trends Microbiol. 2015;23:719–729. doi: 10.1016/j.tim.2015.07.013.
    1. Fuentes S., van Nood E., Tims S., Heikamp-de Jong I., ter Braak C.J., Keller J.J., Zoetendal E.G., de Vos W.M. Reset of a critically disturbed microbial ecosystem: Faecal transplant in recurrent Clostridium difficile infection. ISME J. 2014;8:1621–1633. doi: 10.1038/ismej.2014.13.
    1. Lozupone C.A., Stombaugh J.I., Gordon J.I., Jansson J.K., Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220–230. doi: 10.1038/nature11550.
    1. Levy M., Kolodziejczyk A.A., Thaiss C.A., Elinav E. Dysbiosis and the immune system. Nat. Rev. Immunol. 2017;17:219–232. doi: 10.1038/nri.2017.7.
    1. Lackey D.E., Olefsky J.M. Regulation of metabolism by the innate immune system. Nat. Rev. Endocrinol. 2016;12:15–28. doi: 10.1038/nrendo.2015.189.
    1. Belkaid Y., Hand T.W. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121–141. doi: 10.1016/j.cell.2014.03.011.
    1. Thaiss C.A., Zmora N., Levy M., Elinav E. The microbiome and innate immunity. Nature. 2016;535:65–74. doi: 10.1038/nature18847.
    1. Wu G.D., Chen J., Hoffmann C., Bittinger K., Chen Y.Y., Keilbaugh S.A., Bewtra M., Knights D., Walters W.A., Knight R., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105–108. doi: 10.1126/science.1208344.
    1. David L.A., Maurice C.F., Carmody R.N., Gootenberg D.B., Button J.E., Wolfe B.E., Ling A.V., Devlin A.S., Varma Y., Fischbach M.A., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–563. doi: 10.1038/nature12820.
    1. Pereira F.C., Berry D. Microbial nutrient niches in the gut. Environ. Microbiol. 2017;19:1366–1378. doi: 10.1111/1462-2920.13659.
    1. Lachnit T., Bosch T.C.G., Deines P. Exposure of the Host-Associated Microbiome to Nutrient-Rich Conditions May Lead to Dysbiosis and Disease Development-an Evolutionary Perspective. MBio. 2019;10 doi: 10.1128/mBio.00355-19.
    1. Chu N.D., Smith M.B., Perrotta A.R., Kassam Z., Alm E.J. Profiling Living Bacteria Informs Preparation of Fecal Microbiota Transplantations. PLoS ONE. 2017;12:e0170922. doi: 10.1371/journal.pone.0170922.
    1. Costello S.P., Soo W., Bryant R.V., Jairath V., Hart A.L., Andrews J.M. Systematic review with meta-analysis: Faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment. Pharmacol. Ther. 2017;46:213–224. doi: 10.1111/apt.14173.
    1. Miquel S., Martin R., Rossi O., Bermudez-Humaran L.G., Chatel J.M., Sokol H., Thomas M., Wells J.M., Langella P. Faecalibacterium prausnitzii and human intestinal health. Curr. Opin. Microbiol. 2013;16:255–261. doi: 10.1016/j.mib.2013.06.003.
    1. Reunanen J., Kainulainen V., Huuskonen L., Ottman N., Belzer C., Huhtinen H., de Vos W.M., Satokari R. Akkermansia muciniphila Adheres to Enterocytes and Strengthens the Integrity of the Epithelial Cell Layer. Appl. Environ. Microbiol. 2015;81:3655–3662. doi: 10.1128/AEM.04050-14.
    1. Costello S.P., Hughes P.A., Waters O., Bryant R.V., Vincent A.D., Blatchford P., Katsikeros R., Makanyanga J., Campaniello M.A., Mavrangelos C., et al. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. JAMA. 2019;321:156–164. doi: 10.1001/jama.2018.20046.
    1. Cammarota G., Ianiro G., Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: A systematic review. J. Clin. Gastroenterol. 2014;48:693–702. doi: 10.1097/MCG.0000000000000046.
    1. Davidovics Z.H., Michail S., Nicholson M.R., Kociolek L.K., Pai N., Hansen R., Schwerd T., Maspons A., Shamir R., Szajewska H., et al. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J. Pediatr. Gastroenterol. Nutr. 2019;68:130–143. doi: 10.1097/MPG.0000000000002205.
    1. Whitacre C.C. Sex differences in autoimmune disease. Nat. Immunol. 2001;2:777–780. doi: 10.1038/ni0901-777.
    1. Danska J.S. Sex matters for mechanism. Sci. Transl. Med. 2014;6:258fs240. doi: 10.1126/scitranslmed.3009859.
    1. Arnold A.P., Lusis A.J. Understanding the sexome: Measuring and reporting sex differences in gene systems. Endocrinology. 2012;153:2551–2555. doi: 10.1210/en.2011-2134.
    1. Markle J.G., Frank D.N., Mortin-Toth S., Robertson C.E., Feazel L.M., Rolle-Kampczyk U., von Bergen M., McCoy K.D., Macpherson A.J., Danska J.S. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013;339:1084–1088. doi: 10.1126/science.1233521.
    1. Bolnick D.I., Snowberg L.K., Hirsch P.E., Lauber C.L., Org E., Parks B., Lusis A.J., Knight R., Caporaso J.G., Svanback R. Individual diet has sex-dependent effects on vertebrate gut microbiota. Nat. Commun. 2014;5:4500. doi: 10.1038/ncomms5500.
    1. Freire A.C., Basit A.W., Choudhary R., Piong C.W., Merchant H.A. Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery. Int. J. Pharm. 2011;415:15–28. doi: 10.1016/j.ijpharm.2011.04.069.
    1. Org E., Mehrabian M., Parks B.W., Shipkova P., Liu X., Drake T.A., Lusis A.J. Sex differences and hormonal effects on gut microbiota composition in mice. Gut Microbes. 2016;7:313–322. doi: 10.1080/19490976.2016.1203502.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera